Literature DB >> 7589506

Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool.

L Halbwachs-Mecarelli1, G Bessou, P Lesavre, S Lopez, V Witko-Sarsat.   

Abstract

Proteinase 3, which is known as an intracellular serine protease of neutrophils, was detected at the surface of a subpopulation of freshly isolated PMN. The proportion of PR3-positive and -negative PMN, observed by flow cytometry with anti-PR3 mAbs or ANCA autoantibodies, varies among individuals but is extremely stable for each individual over prolonged time periods. After PMN degranulation by FMLP with cyt. B, membrane PR3 expression increases but the proportion of low and high PR3-expressing cells remains stable. The existence of a subset of PMN which spontaneously expresses PR3 and varies among individuals, may be relevant to the pathogenesis of anti-PR3 ANCA autoantibody-related vasculitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589506     DOI: 10.1016/0014-5793(95)01073-n

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  45 in total

1.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) but not granulocyte colony-stimulating factor (G-CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro.

Authors:  B Hellmich; E Csernok; A Trabandt; W L Gross; M Ernst
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Target antigens for anti-neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils.

Authors:  J J Yang; R H Tuttle; S L Hogan; J G Taylor; B D Phillips; R J Falk; J C Jennette
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

3.  Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity.

Authors:  T Akamizu; S Ozaki; H Hiratani; H Uesugi; J Sobajima; Y Hataya; N Kanamoto; M Saijo; Y Hattori; K Moriyama; K Ohmori; K Nakao
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 4.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

5.  Increased neutrophil membrane expression and plasma level of proteinase 3 in systemic vasculitis are not a consequence of the - 564 A/G promotor polymorphism.

Authors:  M Abdgawad; T Hellmark; L Gunnarsson; K W A Westman; M Segelmark
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 6.  Pathogenesis of ANCA-associated vasculitis.

Authors:  Rodrigo Cartin-Ceba; Tobias Peikert; Ulrich Specks
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 7.  Endothelium-neutrophil interactions in ANCA-associated diseases.

Authors:  Lise Halbwachs; Philippe Lesavre
Journal:  J Am Soc Nephrol       Date:  2012-09       Impact factor: 10.121

Review 8.  How anti-neutrophil cytoplasmic autoantibodies activate neutrophils.

Authors:  R Kettritz
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

Review 9.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

10.  Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils.

Authors:  Brice Korkmaz; Jérôme Jaillet; Marie-Lise Jourdan; Alexandre Gauthier; Francis Gauthier; Sylvie Attucci
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.